Slide 1: CEO Operational Report - Annual General Meeting
For personal use only CEO Operational Report Annual General Meeting 23 October 2013
Slide 2: Leading the Field
Leading the Field For personal use only Clinical Trials Axon Sports Cogstate Research COGNIGRAM™ Playing an integral role Cutting edge tools to Accepted and used Giving GPs tools for in cognition-related assess, monitor and globally in critical accurate, easy clinical trials improve the athletic stu
Slide 3: Clinical Trials
Clinical Trials For personal use only • Cogstate pays an integral role in the global undertaking of cognitive-related clinical trials with 7 out of 10 major pharma companies using Cogstate Test. • FDA Guidance recommends Alzheimer's drug makers should not rely on biomarker data alone to demonstrate
Slide 4: Axon Sports
Axon Sports For personal use only • Elite training systems installed at Human Performance Labs, Training Centres and college/professional team facilities throughout the USA and in the UK. • Provide college and professional athletes advanced cognitive training tools and technology as part of a progra
Slide 5: Cogstate Research
Cogstate Research For personal use only • Cogstate developed a global reputation for engaging in world class research; – Psychological and neuropsychological – Genetic and medical conditions • Wealth of research studies involving Cogstate and the important role that research plays across the busines
Slide 6: Accepted & used in critical studies
Accepted & used in critical studies For personal use only AIBL (Australian Imaging Anti-Amyloid Treatment in Biomarkers & Lifestyle) Asymptomatic AD (A4) Critical prospective studies Dominantly Inherited have all selected Brigham Nurses Health Study Alzheimer’s Network Trials Cogstate as the – Bosto
Slide 7: Cogstate Research use in critical Alzheimer's disease studies
Cogstate Research use in critical Alzheimer’s disease studies For personal use only • Adoption of Cogstate technology by leading international Alzheimer’s disease researchers. • Cogstate selected to participate in worldwide clinical trials investigating early detection of Alzheimer’s - A4 and DIAN t
Slide 8: Healthcare
Healthcare For personal use only • First primary care application of Cogstate technology; an important new tool to assist physicians to evaluate and monitor the cognitive function of the patient over time. • Pilot launched in Canada to GPs by Merck Canada in March 2013. • Over 450 physicians registe
Slide 9: Testing centres established
Testing centres established For personal use only • Canada’s largest provider of home and community health care services; 50 home care offices, 20 community care clinics and 8,000 employees. – 20 sites live today • Testing in larger clinics and specialist centres launched in October 2013 after clear
Slide 10: Reimbursement
Reimbursement For personal use only • Cash payment (in place). • Private reimbursement (available); – Available via Health Spending Account – Create demand for reimbursement from other payers • Public reimbursement (will take time); Example of cash payment – Critical to show reduced cost because of
Slide 11: Specialists support and advocacy
Specialists support and advocacy For personal use only • Advisory board of Canadian Key Opinion Leaders established. • User guide for doctors; – Everything you need to know about the product; history, validation, indications and how to interpret results. • Consultation with Canadian KOLs by Cogstate
Slide 12: Multi-channel marketing campaign
Multi-channel marketing campaign For personal use only Email campaign to 30,000 Canadian physicians • Drive awareness • Invitation to events : Paul Maruff presentation of data from AAIC • Educational material
Slide 13: FY13 Financial Results
FY13 Financial Results For personal use only Revenue $12.46m, 4% Clinical Trials Net Loss $2.12m • Revenue of $11.6m. • Organic growth from larger, later stage contracts and entry into new disease areas. Healthcare • COGNIGRAM test launched in Canada to GPs accounting for major investment of capital
Slide 14: New phase in the evolution of Cogstate
New phase in the evolution of Cogstate For personal use only • New revenue streams in FY13 marks the beginning of new and significant commercial opportunities: – AD testing a $500m pa global market opportunity; Cogstate has an exceptional opportunity to – Cogstate uniquely positioned to capture this
Slide 15: FY14 Business Outlook
FY14 Business Outlook For personal use only $2.7m of sales revenue (which was largely milestone based revenue from contracts on hand) producing cash receipts of $3.7m. Net operating cash outflow of $0.5m for the quarter. Total net cash outflow of $0.24m for the quarter. 1st Quarter Results Cash rese
Slide 16: FY14 Business Outlook
FY14 Business Outlook For personal use only Clinical Trials sales are inherently inconsistent and the quantity of sales contracts signed during Q1 was disappointing. However outstanding sales proposals are higher than the previous year. Clinical Trial FY14 revenue will be dependent upon the ability
Slide 17: For personal use only
For personal use only COGSTA’lhe ASSESS + MONITOR « IMPROVE